Quick Answer
ORTHOPEDIATRICS CORP reported Research And Development Expense of $9.10 million for the year ending 2025.
- ORTHOPEDIATRICS CORP showed a decrease of -17.5% in Research And Development Expense from 2024 to 2025.
- This data is from ORTHOPEDIATRICS CORP's annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), ORTHOPEDIATRICS CORP's Research And Development Expense has grown by 408.8%.
- Historical annual values: Fiscal year 2025: $9.10 million | Fiscal year 2024: $11.03 million | Fiscal year 2023: $10.90 million | Fiscal year 2022: $8.45 million | Fiscal year 2021: $5.54 million | Fiscal year 2020: $5.27 million | Fiscal year 2019: $5.75 million | Fiscal year 2018: $4.73 million | Fiscal year 2017: $3.42 million | Fiscal year 2016: $2.22 million | Fiscal year 2015: $1.79 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: